Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. Issue 9 (1st September 2020)

• Record Type: Journal Article
• Authors: Yang, Xiaolei; Liu, Ye; Liu, Yuping; Yang, Qing; Wu, Xubo; Huang, Xuan; Liu, Huijia; Cai, Weimin; Ma, Guo
• Is Part Of: Expert review of clinical pharmacology. Volume 13:Issue 9(2020)
• Page Start: 957
• Page End: 975
• Publication Date: 2020-09-01
• Subjects: Coronavirus disease -- COVID-19 -- SARS-CoV-2 -- medication therapy -- therapeutic strategies; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1080/17512433.2020.1805315
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: Introduction: The coronavirus disease 2019 (COVID-19) pandemic has spread globally since it outbroke in December 2019. The urgent pandemic presents an unprecedented challenge to develop and identify effective medication therapy strategies to combat the COVID-19. Areas covered: Here, we summarized and evaluated the current treatment drugs and regimens, and put forward the treatment recommendations, including using the potential repurposed or experimental drugs against COVID-19, e.g. chloroquine (CQ), hydroxychloroquine (HCQ), lopinavir/ritonavir (LPV/r), remdesivir (RDV), and favipiravir (FPV). We also analyzed the specific drugs and vaccines against SARS-CoV-2 ongoing development and formulated the comprehensive treatment regimens based on condition of patients, diseases and drugs as well as concomitant medications. Expert opinion: No drugs and vaccines have been proven to be particularly effective against SARS-CoV-2 up to now. The recommended comprehensive medication therapy strategies have already displayed favorable effect in the fight against COVID-19. Research should be focused on the development of anti-SARS-CoV-2 drugs and vaccines based on high-quality clinical trial evidence, treatment guidelines and expert consensus.